Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Preventing Postoperative Immunosuppression by Targeted Exosome Delivery of shRNA to Knockdown PI3Kgamma Signalling in Surgery-Induced Myeloid Derived Suppressor Cells
EF 2023-24
Résumé
Surgery is the primary treatment for solid malignancies and evidence shows that surgical stress causes physiological changes in the body. This alters the tumour microenvironment and increases metastasis through the activation of innate and adaptive immune systems. Surgery-induced myeloid-derived suppressor cells (Sx-MDSCs) have been shown to play a key immunosuppressive role post-operatively by directly suppressing Natural Killer (NK) cells, cells which are critical to differentiating between malignant and normal cells. Targeting the PI3Kgamma pathway in sx-MDSCs with an inhibitor has been shown to decrease their suppressive ability, thus restoring the function of NK cells. We would like to test if inhibition using short hairpin RNA (shRNA) is effective at reducing PI3Kgamma function. The delivery system of the shRNA would be done using extracellular vesicles (EVs), such as exosomes, which are particles released from cells to mediate intracellular communications. Recent studies show they can be customized and used to deliver small molecules to target cells with low toxicity. Also, specificity of the treatment is important to mitigate off-target effects, and this can be done by targeting the exosomes to the CD155 receptor on sx-MDSCs. Previously, the Auer lab discovered through a screen of cell surface markers on Sx-MDSCs, the CD155 marker was detected at high intensity after surgery (POD1) and low at baseline (BL). This makes it an attractive perioperative target for immunotherapy. Currently there are no effective therapies that specifically target the immunosuppression induced during the perioperative period. This treatment strategy could decrease this immunosuppression and reduce incidences of tumour recurrence in Canadian cancer patients undergoing surgery.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506516
Name
MacDonald Reagan A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Preventing Postoperative Immunosuppression by Targeted Exosome Delivery of shRNA to Knockdown PI3Kgamma Signalling in Surgery-Induced Myeloid Derived Suppressor Cells
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cd155; Exosomes; Immunology; Immunotherapy; Pi3kgamma; Shrna; Surgery; Surgery-Induced Myeloid Derived Suppressor Cells; Transduction
Abstract
Surgery is the primary treatment for solid malignancies and evidence shows that surgical stress causes physiological changes in the body. This alters the tumour microenvironment and increases metastasis through the activation of innate and adaptive immune systems. Surgery-induced myeloid-derived suppressor cells (Sx-MDSCs) have been shown to play a key immunosuppressive role post-operatively by directly suppressing Natural Killer (NK) cells, cells which are critical to differentiating between malignant and normal cells. Targeting the PI3Kgamma pathway in sx-MDSCs with an inhibitor has been shown to decrease their suppressive ability, thus restoring the function of NK cells. We would like to test if inhibition using short hairpin RNA (shRNA) is effective at reducing PI3Kgamma function. The delivery system of the shRNA would be done using extracellular vesicles (EVs), such as exosomes, which are particles released from cells to mediate intracellular communications. Recent studies show they can be customized and used to deliver small molecules to target cells with low toxicity. Also, specificity of the treatment is important to mitigate off-target effects, and this can be done by targeting the exosomes to the CD155 receptor on sx-MDSCs. Previously, the Auer lab discovered through a screen of cell surface markers on Sx-MDSCs, the CD155 marker was detected at high intensity after surgery (POD1) and low at baseline (BL). This makes it an attractive perioperative target for immunotherapy. Currently there are no effective therapies that specifically target the immunosuppression induced during the perioperative period. This treatment strategy could decrease this immunosuppression and reduce incidences of tumour recurrence in Canadian cancer patients undergoing surgery.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
MacDonald, Reagan A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~